MiNK Therapeutics (NASDAQ:INKT) Shares to Reverse Split on Tuesday, January 28th

Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) are going to reverse split before the market opens on Tuesday, January 28th. The 1-10 reverse split was announced on Tuesday, January 21st. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, January 27th.

MiNK Therapeutics Stock Performance

Shares of MiNK Therapeutics stock opened at $0.98 on Friday. The stock has a market cap of $38.64 million, a price-to-earnings ratio of -2.50 and a beta of 0.10. The stock has a 50 day moving average price of $0.71 and a 200-day moving average price of $0.77. MiNK Therapeutics has a one year low of $0.46 and a one year high of $1.90.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on INKT. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of MiNK Therapeutics in a research note on Friday, November 15th. Robert W. Baird decreased their price target on MiNK Therapeutics from $8.00 to $4.00 and set an “outperform” rating for the company in a research note on Friday, November 15th.

Institutional Investors Weigh In On MiNK Therapeutics

An institutional investor recently raised its position in MiNK Therapeutics stock. Renaissance Technologies LLC raised its position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 21.5% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 127,841 shares of the company’s stock after purchasing an additional 22,613 shares during the period. Renaissance Technologies LLC owned about 0.37% of MiNK Therapeutics worth $121,000 as of its most recent filing with the Securities & Exchange Commission. 2.87% of the stock is currently owned by institutional investors.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.